Growth Metrics

Jazz Pharmaceuticals (JAZZ) Short term Debt (2016 - 2025)

Jazz Pharmaceuticals has reported Short term Debt over the past 16 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly Short term Debt rose 3222.27% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 3222.27% year-over-year, with the annual reading at $1.0 billion for FY2025, 3222.27% up from the prior year.
  • Short term Debt was $1.0 billion for Q4 2025 at Jazz Pharmaceuticals, roughly flat from $1.0 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $1.0 billion in Q4 2025 and troughed at $31.0 million in Q3 2021.
  • The 5-year median for Short term Debt is $31.0 million (2021), against an average of $317.3 million.
  • Peak annual rise in Short term Debt hit 3222.27% in 2025, while the deepest fall reached 94.88% in 2025.
  • Tracing JAZZ's Short term Debt over 5 years: stood at $31.0 million in 2021, then changed by 0.0% to $31.0 million in 2022, then surged by 1851.46% to $605.0 million in 2023, then tumbled by 94.88% to $31.0 million in 2024, then surged by 3222.27% to $1.0 billion in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $1.0 billion, $1.0 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.